II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies

• Published in: Einstein (São Paulo, Brazil) Brazil), 2017-01, Vol.15 (1), p.1-16
• Main Authors: Goudouris, Ekaterini Simões, Rego Silva, Almerinda Maria do, Ouricuri, Aluce Loureiro, Grumach, Anete Sevciovic, Condino-Neto, Antonio, Costa-Carvalho, Beatriz Tavares, Prando, Carolina Cardoso, Kokron, Cristina Maria, Vasconcelos, Dewton de Moraes, Tavares, Fabíola Scancetti, Silva Segundo, Gesmar Rodrigues, Barreto, Irma Cecília, Dorna, Mayra de Barros, Barros, Myrthes Anna, Forte, Wilma Carvalho Neves
• Format: Article
• Language: eng ; por
• Subjects: Administration, Cutaneous; Administration, Intravenous; Brazil; Consensus; Doenças do sistema imune; Humans; Immunoglobulins - therapeutic use; Immunologic Deficiency Syndromes; Immunologic Factors - supply & distribution; Immunologic Factors - therapeutic use; Imunização passiva; Imunoglobulinas; Imunoglobulinas intravenosas; MEDICINE, GENERAL & INTERNAL; Special; Síndromes de imunodeficiência; Treatment Outcome
• ISSN: 1679-4508; 2317-6385; 2317-6385; 1679-4508
• DOI: 10.1590/S1679-45082017AE3844

In the last few years, new primary immunodeficiencies and genetic defects have been described. Recently, immunoglobulin products with improved compositions and for subcutaneous use have become available in Brazil. In order to guide physicians on the use of human immunoglobulin to treat primary immunodeficiencies, based on a narrative literature review and their professional experience, the members of the Primary Immunodeficiency Group of the Brazilian Society of Allergy and Immunology prepared an updated document of the 1st Brazilian Consensus, published in 2010. The document presents new knowledge about the indications and efficacy of immunoglobulin therapy in primary immunodeficiencies, relevant production-related aspects, mode of use (routes of administration, pharmacokinetics, doses and intervals), adverse events (major, prevention, treatment and reporting), patient monitoring, presentations available and how to have access to this therapeutic resource in Brazil.